文献速递泌尿男性生殖肿瘤

尼拉帕利联合醋酸阿比特龙和泼尼松治疗携带同源重组修复基因改变的转移性去势抵抗性前列腺癌患者:随机III期MAGNITUDE试验第二次中期分析

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.
PubMed 文献 · Ann Oncol · 2023-07-01

MAGNITUDE试验第二次中期分析纳入HRR+的mCRPC患者,随机接受尼拉帕利联合AAP或安慰剂联合AAP。在BRCA1/2亚组中,尼拉帕利联合AAP显著延长影像学无进展生存期(中位19.5 vs 10.9个月;HR=0.55,95%CI 0.39-0.78;名义P=0.0007)。总HRR+人群rPFS也延长(HR=0.76,95%CI 0.60-0.97;名义P=0.0280)。未观察到新的安全性信号。

要点

  • BRCA1/2改变的mCRPC患者中,尼拉帕利联合AAP较安慰剂联合AAP显著延长rPFS(中位19.5 vs 10.9个月;HR=0.55)。
  • 总HRR+人群中rPFS也延长(HR=0.76,95%CI 0.60-0.97;名义P=0.0280)。
  • BRCA1/2亚组OS的HR为0.88(95%CI 0.58-1.34;名义P=0.5505),未达统计学显著。

核心结论

  • 在BRCA1/2改变的mCRPC患者中,尼拉帕利联合AAP改善了rPFS及其他临床相关结局,强调识别该分子亚组患者的重要性。

研究设计与样本

  • 随机III期MAGNITUDE试验第二次预先设定的中期分析(IA2)。
  • 患者为前瞻性鉴定的HRR+ mCRPC患者(伴或不伴BRCA1/2改变),按1:1随机接受尼拉帕利(200 mg口服)联合AAP(1000 mg/10 mg口服)或安慰剂联合AAP。
  • 共212例HRR+患者接受尼拉帕利联合AAP,其中BRCA1/2亚组113例。

主要发现

  • BRCA1/2亚组中位随访24.8个月,尼拉帕利联合AAP较安慰剂联合AAP显著延长rPFS(盲态独立中心评估;中位19.5 vs 10.9个月;HR=0.55,95%CI 0.39-0.78;名义P=0.0007)。
  • 总HRR+人群中位随访26.8个月,rPFS也延长(HR=0.76,95%CI 0.60-0.97;名义P=0.0280)。
  • 尼拉帕利联合AAP在至症状进展时间和至开始细胞毒性化疗时间方面观察到改善。
  • BRCA1/2亚组中,尼拉帕利联合AAP的OS分析HR为0.88(95%CI 0.58-1.34;名义P=0.5505);预先设定的逆概率删失加权分析(校正后续PARP抑制剂和其他延长生存治疗的不平衡)显示HR为0.54(95%CI 0.33-0.90;名义P=0.0181)。
  • 未观察到新的安全性信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous recombination repair gene alterations (HRR+), particularly BRCA1/2, benefit from first-line therapy with niraparib plus abiraterone acetate and prednisone (AAP). Here we report longer follow-up from the second prespecified interim analysis (IA2). PATIENTS AND METHODS: Patients with mCRPC were prospectively identified as HRR+ with/without BRCA1/2 alterations and randomized 1 : 1 to niraparib (200 mg orally) plus AAP (1000 mg/10 mg orally) or placebo plus AAP. At IA2, secondary endpoints [time to symptomatic progression, time to initiation of cytotoxic chemotherapy, overall survival (OS)] were assessed. RESULTS: Overall, 212 HRR+ patients received niraparib plus AAP (BRCA1/2 subgroup, n = 113). At IA2 with 24.8 months of median follow-up in the BRCA1/2 subgroup, niraparib plus AAP significantly prolonged radiographic progression-free survival {rPFS; blinded independent central review; median rPFS 19.5 versus 10.9 months; hazard ratio (HR) = 0.55 [95% confidence interval (CI) 0.39-0.78]; nominal P = 0.0007} consistent with the first prespecified interim analysis. rPFS was also prolonged in the total HRR+ population [HR = 0.76 (95% CI 0.60-0.97); nominal P = 0.0280; median follow-up 26.8 months]. Improvements in time to symptomatic progression and time to initiation of cytotoxic chemotherapy were observed with niraparib plus AAP. In the BRCA1/2 subgroup, the analysis of OS with niraparib plus AAP demonstrated an HR of 0.88 (95% CI 0.58-1.34; nominal P = 0.5505); the prespecified inverse probability censoring weighting analysis of OS, accounting for imbalances in subsequent use of poly adenosine diphosphate-ribose polymerase inhibitors and other life-prolonging therapies, demonstrated an HR of 0.54 (95% CI 0.33-0.90; nominal P = 0.0181). No new safety signals were observed. CONCLUSIONS: MAGNITUDE, enrolling the largest BRCA1/2 cohort in first-line mCRPC to date, demonstrated improved rPFS and other clinically relevant outcomes with niraparib plus AAP in patients with BRCA1/2-altered mCRPC, emphasizing the importance of identifying this molecular subset of patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Chi KN, Sandhu S, Smith MR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023. PMID: 37399894. doi:10.1016/j.annonc.2023.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。